Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the ability of AI to correctly aid in
characterization of benign and malignant lesions even when a low dose of gadolinium is
administered. This study is relevant for several reasons, most notably being the reduction of
MRI dose and decreased gadolinium deposition in the brain. In addition, use of AI may provide
increased sensitivity and specificity for the radiologist evaluating a breast MRI exam. Half
of the population will have benign pathologies and the other half will have malignant
pathologies.